GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHF) » Definitions » PS Ratio

SHPHF (Sihuan Pharmaceutical Holdings Group) PS Ratio : 1.89 (As of Dec. 15, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sihuan Pharmaceutical Holdings Group's share price is $0.0492. Sihuan Pharmaceutical Holdings Group's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.03. Hence, Sihuan Pharmaceutical Holdings Group's PS Ratio for today is 1.89.

Warning Sign:

Sihuan Pharmaceutical Holdings Group Ltd stock PS Ratio (=3.11) is close to 1-year high of 3.38

The historical rank and industry rank for Sihuan Pharmaceutical Holdings Group's PS Ratio or its related term are showing as below:

SHPHF' s PS Ratio Range Over the Past 10 Years
Min: 1.71   Med: 4.69   Max: 15.74
Current: 3.32

During the past 13 years, Sihuan Pharmaceutical Holdings Group's highest PS Ratio was 15.74. The lowest was 1.71. And the median was 4.69.

SHPHF's PS Ratio is ranked worse than
61.09% of 974 companies
in the Drug Manufacturers industry
Industry Median: 2.34 vs SHPHF: 3.32

Sihuan Pharmaceutical Holdings Group's Revenue per Sharefor the six months ended in Jun. 2024 was $0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.03.

Warning Sign:

Sihuan Pharmaceutical Holdings Group Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Sihuan Pharmaceutical Holdings Group was -2.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was -10.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was -7.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was -3.00% per year.

During the past 13 years, Sihuan Pharmaceutical Holdings Group's highest 3-Year average Revenue per Share Growth Rate was 71.40% per year. The lowest was -10.80% per year. And the median was 3.30% per year.

Back to Basics: PS Ratio


Sihuan Pharmaceutical Holdings Group PS Ratio Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group PS Ratio Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.75 2.69 3.78 3.64 2.97

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3.64 - 2.97 -

Competitive Comparison of Sihuan Pharmaceutical Holdings Group's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sihuan Pharmaceutical Holdings Group's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's PS Ratio distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's PS Ratio falls into.



Sihuan Pharmaceutical Holdings Group PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Sihuan Pharmaceutical Holdings Group's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.0492/0.026
=1.89

Sihuan Pharmaceutical Holdings Group's Share Price of today is $0.0492.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sihuan Pharmaceutical Holdings Group's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Sihuan Pharmaceutical Holdings Group  (OTCPK:SHPHF) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Sihuan Pharmaceutical Holdings Group PS Ratio Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sihuan Pharmaceutical Holdings Group Business Description

Traded in Other Exchanges
Address
Zhubang 2000, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segments; and the generic medicine segment which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.